Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 14:46:56 GMT 2023
by
admin
on
Sat Dec 16 14:46:56 GMT 2023
|
| Protein Type | RECEPTOR |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
UN0FN8L6YG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
UN0FN8L6YG
Created by
admin on Sat Dec 16 14:46:56 GMT 2023 , Edited by admin on Sat Dec 16 14:46:56 GMT 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_7 | 1_34 |
| 1_133 | 1_163 |
| 1_166 | 1_175 |
| 1_170 | 1_183 |
| 1_191 | 1_199 |
| 1_195 | 1_207 |
| 1_208 | 1_216 |
| 1_212 | 1_224 |
| 1_227 | 1_236 |
| 1_240 | 1_267 |
| 1_271 | 1_283 |
| 1_287 | 1_302 |
| 1_305 | 1_309 |
| 1_313 | 1_338 |
| 1_446 | 1_475 |
| 1_482 | 1_491 |
| 1_486 | 1_499 |
| 1_502 | 1_511 |
| 1_515 | 1_531 |
| 1_534 | 1_547 |
| 1_538 | 1_555 |
| 1_558 | 1_567 |
| 1_571 | 1_593 |
| 1_596 | 1_604 |
| 1_600 | 1_612 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_32 |
| N | 1_49 |
| N | 1_104 |
| N | 1_151 |
| N | 1_172 |
| N | 1_328 |
| N | 1_337 |
| N | 1_389 |
| N | 1_420 |
| N | 1_504 |
| N | 1_544 |
| N | 1_579 |
| N | 1_599 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET |
Uncommon EGFR mutations, including L861Q, G719X, and/or S768I
|
||
|
NON-INHIBITOR->OFF TARGET |
Overall survival (OS) was significantly shorter among patients with uncommon EGFR mutations (G719X or L861Q) com-pared with OS of those with common EGFR mutations (12 versus 28.4 months; p = 0.002). In the gefitinib group (n = 114), patients with uncommon EGFR mutations had a significantly shorter OS (11.9 versus 29.3 months; p < 0.001). By contrast, OS was similar between patients with uncommon mutations and those with common mutations in the carboplatin-paclitaxel group (n = 111; 22.8 versus 28 months; p = 0.358)
|
||
|
INHIBITOR -> TARGET |
a case of successful treatment of a patient aged >80 years with lung adenocarcinoma positive for the uncommon EGFR L861Q mutation with low‐dose afatinib. An 83‐year‐old woman presented with cough and dyspnea. A chest computed tomography (CT) scan revealed tumors in the left upper lobe, left pleural effusion, and multiple lung metastases in both lungs. The patient was diagnosed with lung adenocarcinoma with an EGFR L861Q mutation based on cytological findings. The patient received 30 mg/day of afatinib and experienced no severe adverse events.
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|